Adagene (ADAG) Total Debt (2019 - 2026)
Adagene (ADAG) posted quarterly Total Debt of $1849.5 billion for Q4 2025, down 86.14% year-over-year from $13340.9 billion in Q4 2024, and up 40738566.17% quarter-over-quarter from $4.5 million in Q2 2025.
Analysis
Adagene (ADAG) Total Debt (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Total Debt for 7 consecutive years, with $1849.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Debt fell 86.14% year-over-year to $1849.5 billion; the TTM figure through Dec 2025 stood at $1849.5 billion (down 86.14% YoY), while the FY2025 annual figure was $1849.5 billion, down 86.14% from the prior year.
- Total Debt rose to $1849.5 billion in Q4 2025 per ADAG's latest filing, from $4.5 million in the prior quarter.
- Across five years, Total Debt topped out at $17701.6 billion in Q4 2023 and bottomed at $3.4 million in Q4 2021.
- Historically, Total Debt has averaged $7644.4 billion across 5 years, with a median of $6231.0 billion in 2022.
- Annual changes were most pronounced in 2022 — Total Debt soared 507243989.22% — and 2024, when it sank 100.0%.
- Adagene's Total Debt stood at $3.4 million in 2021, then jumped by 507243989.22% to $16996.7 billion in 2022, then climbed by 4.15% to $17701.6 billion in 2023, then fell by 24.63% to $13340.9 billion in 2024, then tumbled by 86.14% to $1849.5 billion in 2025.
- Business Quant data shows ADAG's Total Debt at $1849.5 billion in Q4 2025, $4.5 million in Q2 2025, and $13340.9 billion in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1.07 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 9.34 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Adagene | 213.60 Mn | 213.60 Mn | - | 5.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.73 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Dec 31, 2024 | 18.21 Mn |
| Jun 30, 2024 | 20.54 Mn |
| Dec 31, 2023 | 21.94 Mn |
| Jun 30, 2023 | 24.94 Mn |
| Dec 31, 2022 | 27.77 Mn |
| Jun 30, 2022 | 16.57 Mn |
| Dec 31, 2021 | 7.49 Mn |
| Jun 30, 2021 | 7.67 Mn |
| Dec 31, 2020 | 7.98 Mn |
| Dec 31, 2019 | 2.56 Mn |